title: [Metabolic correction of the lipid-transport system in experimental diffuse purulent peritonitis].
abstract: The research was performed in 55 male chinchilla rabbits. For the first time the effect of metabolic preparations "citoflavin" and "neoton" of the protein-lipid spectrum of blood was studied in experimental diffuse purulent peritonitis. The development of diffuse purulent peritonitis caused negative changes in blood lipid-transport system which resulted in a decreased blood protein level and high density lipoproteins (HDL) and growth of triglycerides. In the HDL phospholipid spectrum the pathological changes are characterized by an increased lisophosphotide content and compensatory growth of the level of poliglycerophosphatides. A comparative analysis has shown that both preparations possess unidirectional action which is more pronounced in "citoflavin" than in "neoton".
authors.forename: V A
authors.initials: VA
authors.lastname: Kosinets
mesh_terms: D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D003131:Combined Modality Therapy; D004338:Drug Combinations; D016903:Drug Monitoring / Q000379:methods; D005486:Flavin Mononucleotide / Q000008:administration & dosage / Q000493:pharmacokinetics; D007262:Infusions, Intravenous / Q000379:methods; D007290:Inosine Diphosphate / Q000008:administration & dosage / Q000493:pharmacokinetics; D007813:Laparotomy; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D023421:Models, Animal; D009536:Niacinamide / Q000008:administration & dosage / Q000493:pharmacokinetics; D010533:Peritoneal Lavage; D010538:Peritonitis / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D010725:Phosphocreatine / Q000008:administration & dosage / Q000493:pharmacokinetics; D020011:Protective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D011817:Rabbits; D058028:Research Report; D013386:Succinates / Q000008:administration & dosage / Q000493:pharmacokinetics; D013492:Suppuration / Q000378:metabolism / Q000628:therapy; D013997:Time Factors; D016896:Treatment Outcome; D014815:Vitamins / Q000008:administration & dosage / Q000493:pharmacokinetics
chemical_list: D004338:Drug Combinations; D020011:Protective Agents; D013386:Succinates; D014815:Vitamins; C507879:cytoflavin; D010725:Phosphocreatine; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate